ClinicalTrials.gg
RecruitingNCT07125950Updated Oct 15, 2026

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

A Phase 2 interventional study of SHR2554 and HRS-8080 in Advanced Breast Cancer, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Henan Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Breast Neoplasms by Henan Cancer Hospital — 29 open to participants now, 32 under way, 3 of them phase 3. Breast Neoplasms · Henan Cancer Hospital.

Planned enrollment
36th of 40
30 · median 77
Started
2025
with 10 others
Phase 2
29 of 45
18 open now
Primary completion
2027-09
later than 19 of 31 live
Registered
41st of 45
by date

Among the 45 studies in Breast Neoplasms by Henan Cancer Hospital, this one is the 36th largest by planned enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2025, is one of 29 in phase 2, reaches primary completion later than 19 of the 31 other live ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

29 of the 45 studies in Breast Neoplasms by Henan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Breast Neoplasms by Henan Cancer Hospital, or all of them as a file.
02

Study summary

This study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 in advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years old, patients with advanced or breast cancer;
  • PS Score: 0\~1;
  • Based on v1.1, at least one ;
  • Patients must have a ≥ 3 months;
  • Adequate organ function and marrow function (no corrective treatment within 14 days before first dose);
  • Women of (WOCBP) should agree to use an effective method of and no lactation from the initiation of screening to 7 months after the last dose of study therapy; WOCBP should have a negative serum pregnancy result within 7 days before the first dose of study therapy; if unneutered male subjects (including using other sterilization except bilateral orchidectomy [e.g. vasectomy]) are willing to have sexual behaviour with WOCBP, one kind of contraception must be used to prevent the pregnancy of his partner from the date of enrolment to 7 months after the last dose of study therapy);
  • Willing and able to provide written and comply with the requirements and restrictions in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Has received or been receiving ADC therapy;
  • Active (without medical control or having clinical symptoms), carcinomatous meningitis or spinal compression;
  • Existence of third space fluid (e.g. massive ascites, pleural effusion) which is not well controlled by effective methods, e.g. drainage, evaluated by investigators;
  • Other within prior 2 years with no necessary treatment (except hormone replacement treatment) for at least recent 2 years, except: curatively treated in situ cancer of the cervix, skin basal cell carcinoma, skin squamous cell carcinoma or papillary thyroid carcinoma;
  • Has received antitumor surgery, radiotherapy, chemotherapy, targeted therapy or immunological therapy within 2 weeks or 5-fold half-life of drugs (whichever is shorter) before first dose of study therapy; has received antitumor endocrine therapy within one week before first dose of study therapy;
  • Adverse events caused by prior antitumor therapy have not recovered to ≤grade 1 per v5.0 (except alopecia and tolerable, chronic grade 2 toxicity determined by investigator);
  • Use of other antitumor systemic treatment during the study;
  • Has received median or potent inhibitors within 2 weeks before the first dose, or CYP3A4 median or potent inducers within 4 weeks before the first dose, or been receiving known CYP3A5 median or potent inhibitors or inducers;
  • to study therapy or any of its ;
  • Uncontrolled chronic, systemic complicating disease evaluated by investigators (e.g. severe, chronic pulmonary, hepatic, renal or heart disease);
  • Known history of immunodeficiency, including -positive, other acquired or innate immunodeficient disease, or known history of organ transplantation, or known history of allogenic haemopoietic stem cell transplantation;
  • Has active (HBsAg-positive and HBV DNA≥500 IU/mL), (positive for HCV antibody and HCV RNA above ) and hepatic cirrhosis;
  • Has an active infection requiring antibiotics, antiviral or antifungal treatment, or pyrexia >38.5℃ of unknown origin during the screening period before first dose of study therapy (patients with pyrexia due to cancer could be enrolled determined by investigator);
  • Known clinically severe cardiac-cerebral vascular disease, including: (1) congestive heart failure ( Class >2); (2) unstable angina pectoris; (3) myocardial infarction over the past year; (4) any supraventricular or ventricular arrhythmia needed to treat or intervene; abnormality of clinical significance evaluated by investigators; existence of arterial/venous thrombotic event within 6 months before first dose, or cerebrovascular accidents, or ;
  • Inability to take oral medication (e.g., unable to swallow, intestinal obstruction), or any active gastrointestinal disease or other condition resulting in inability to drug absorption, distribution, metabolism or excretion (e.g., active gastroenteritis, chronic diarrhoea, intestinal syndrome, or upper gastrointestinal surgery, including gastrectomy);
  • Other conditions that might influence the study and analysis of results in the opinion of the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SHR2554 + HRS-8080

    SHR2554 + HRS-8080

    Drug: SHR2554 · Drug: HRS-8080

Interventions

06

What researchers measure

Primary outcomes

  1. ORR by investigator

    ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR (complete response) or PR (partial response) per RECIST v1.1.

    Time frame: At baseline, at the time point of every 8 weeks within first 24 weeks, thereafter every 12 weeks

Secondary outcomes

  1. CBR by investigator

    CBR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR (complete response), PR (partial response) or SD (stable disease)≥6 months per RECIST v1.1.

    Time frame: At baseline, at the time point of every 8 weeks within first 24 weeks, thereafter every 12 weeks

  2. DoR

    DoR is the time from the date of first detection of objective response (which is subsequently confirmed) until the date of objective radiographic disease progression.

    Time frame: up to 3 years

  3. PFS

    PFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression).

    Time frame: up to 3 years

  4. OS

    OS is the time from the date of first dose until the date of death by any cause.

    Time frame: up to 3 years

  5. Safety (Proportion of AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. Percentage of participants who experienced an adverse event and discontinued study drug due to an AE.

    Time frame: from time of informed consent provided to 30 days after the last dose of study therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 15, 2025
StartActual
Oct 14, 2025was Sep 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Jan 31, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
Henan Cancer Hospital is now Recruiting
Oct 15, 2026
Start date
Sep 30, 2025→Oct 14, 2025 (actual)
Oct 15, 2026
Enrollment
60→30
Oct 15, 2026
Eligibility
Maximum age 75 Years→none; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited≥ 18 years to 75 years old (including boundary values), patients with advanced or metastatic breast cancer;
Oct 15, 2026
Interventions
Removed Drug: HRS-1358. Arms added: SHR2554 + HRS-8080; arms removed: Arm1·Arm2
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Henan Cancer Hospital is now Recruiting
    Start date Sep 30, 2025→Oct 14, 2025 (now actual)
    Enrollment 60→30
    Eligibility Maximum age 75 Years→none; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited≥ 18 years to 75 years old (including boundary values), patients with advanced or metastatic breast cancer;
    Interventions Removed Drug: HRS-1358. Arms added: SHR2554 + HRS-8080; arms removed: Arm1·Arm2
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07125950
Responsible party
Min Yan, MD (Chief physician, Henan Cancer Hospital) — Principal investigator
First posted
Aug 15, 2025
Start date
Oct 14, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Min Yan, Chief physician
Contact
ym200678@126.com
+86-15713857388
Limin Niu, Physician-in-charge
Contact
1412113302@qq.com
+86-15838271475
Min Yan, Chief physician
principal investigator · Henan Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion